Antibody-peptide conjugates for targeted inhibition of cysteine proteases

E. Oricchio 

Antibody-peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins

A. S. Petruzzella; M. Bruand; A. Santamaria-Martinez; N. Katanayeva; L. Reymond et al. 

Cancer Evolution: A Multifaceted Affair

G. Ciriello; L. Magnani; S. J. Aitken; L. Akkari; S. Behjati et al. 

Development of cysteine cathepsin inhibitors combined with cell type-specific delivery for the treatment of B-cell lymphoma and solid tumors

Cis-regulatory effect of HPV integration is constrained by host chromatin architecture in cervical cancers

A. K. Singh; K. Walavalkar; D. Tavernari; G. Ciriello; D. Notani et al. 

CellCharter reveals spatial cell niches associated with tissue remodeling and cell plasticity

M. Varrone; D. Tavernari; A. Santamaria-Martinez; L. A. Walsh; G. Ciriello 

Whole-genome doubling drives oncogenic loss of chromatin segregation

R. A. Lambuta; L. Nanni; Y. Liu; J. Diaz-Miyar; A. Iyer et al. 

Whole genome doubling promotes tumorigenesis through loss of chromatin segregation and compartment repositioning

Chromatin organization in red triangles

E. Oricchio 

New approaches to uncover the minimally functional hematopoietic niche using the adipocytic differentiation axis: pharmacological modulation and adrenal niche induction

De Novo Design of Site-specific Protein Binders Using Surface Fingerprints

S. Wehrle; A. Van Hall-Beauvais; P. Gainza; Z. Harteveld; A. Scheck et al. 

Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression

D. Tavernari; E. Battistello; E. Dheilly; A. S. Petruzzella; M. Mina et al. 

Histone acetylation dynamics modulates chromatin conformation and allele-specific interactions at oncogenic loci

S. Sungalee; Y. Liu; R. A. Lambuta; N. Katanayeva; M. Donaldson Collier et al. 

Genomic studies indicate a novel combination therapy for follicular lymphoma COMMENT

E. Oricchio; H-G. Wendel 

Cathepsin inhibitors and uses thereof

E. Oricchio; E. Battistello; M. Santin; L. Reymond 

Systematic inference and comparison of multi-scale chromatin sub-compartments connects spatial organization to cell phenotypes

Y. Liu; L. Nanni; S. Sungalee; M. Zufferey; D. Tavernari et al. 

The Tumor Microenvironment as a Driving Force of Breast Cancer Stem Cell Plasticity

F. Fico; A. Santamaria-Martinez 

TGFBI modulates tumour hypoxia and promotes breast cancer metastasis

F. Fico; A. Santamaria-Martinez 

De novo protein design enables the precise induction of RSV-neutralizing antibodies

F. Sesterhenn; C. Yang; J. Bonet; J. T. Cramer; X. Wen et al. 

Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma

E. Dheilly; E. Battistello; N. Katanayeva; S. J. Sungalee; J. Michaux et al. 

A scalable CRISPR/Cas9-based fluorescent reporter assay to study DNA double-strand break repair choice

P. Roidos; S. Sungalee; S. Benfatto; O. Sercin; A. M. Stuetz et al. 

Allosteric regulation and targeting of Bruton’s tyrosine kinase (Btk) in B-cell lymphoma

Genome-wide Screens Implicate Loss of Cullin Ring Ligase 3 in Persistent Proliferation and Genome Instability in TP53-Deficient Cells

A. P. Drainas; R. A. Lambuta; I. Ivanova; O. Sercin; I. Sarropoulos et al. 

EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains

M. C. Donaldson; S. J. Sungalee; M. Zufferey; D. Tavernari; N. Katanayeva et al. 

Histone Modifications in Development and Malignancy

E. Oricchio 

A Tale of Two Tumors: Unraveling the Complexities of Epigenetic Dysregulation in Cancer

Novel therapeutic strategies targeting the B-cell receptor signaling and antigen presentation pathways in non-Hodgkin lymphoma

Comparison of computational methods for the identification of topologically associating domains

M. Zufferey; D. Tavernari; E. Oricchio; G. Ciriello 

Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity

E. Dheilly; S. Majocchi; V. Moine; G. Didelot; L. Broyer et al. 

Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma

E. Battistello; N. Katanayeva; E. Dheilly; D. Tavernari; M. Donaldson et al. 

Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies

M. Mina; F. Raynaud; D. Tavernari; E. Battistello; S. Sungalee et al. 

Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma

E. Oricchio; N. Katanayeva; M. C. Donaldson; S. Sungalee; P. P. Joyce et al. 

Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells

M. Boice; D. Salloum; F. Mourcin; V. Sanghvi; R. Amin et al. 

Generation and characterization of a single-chain anti-EphA2 antibody

Y. Goldgur; P. Susi; E. Karelehto; H. Sanmark; U. Lamminmäki et al. 

A cell engineering strategy to enhance the safety of stem cell therapies

E. Oricchio; E. P. Papapetrou; F. Lafaille; Y. M. Ganat; S. Kriks et al. 

Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy

E. Oricchio; G. Ciriello; M. Jiang; M. H. Boice; J. H. Schatz et al. 

Progress against follicular lymphoma

J. H. Schatz; E. Oricchio; S. D. Puvvada; H. G. Wendel 

Functional genomics lead to new therapies in follicular lymphoma

E. Oricchio; H-G. Wendel 

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

J. H. Schatz; E. Oricchio; A. L. Wolfe; M. Jiang; I. Linkov et al. 

The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma

E. Oricchio; G. Nanjangud; A. L. Wolfe; J. H. Schatz; K. J. Mavrakis et al.